Abstract:Hemophilia A is a bleeding disorder due to the deficiency of coagulation factor VIII (FVIII). According to resident FVIII activity, the disease was divided into mild type (FVIII:c > 5 IU/dL), moderate type (FVIII:c 1–5 IU/dL) and severe type (FVIII:c < 1 IU/dL). Patients with severe hemophilia A suffered from frequent spontaneous bleeding, which could destroy the normal joint structure and lead to serious disfunction if the bleeding happened in soft issue and joints. Nowadays, prophylaxis is considered as the optimized treatment of hemophilia A [ [1] Iorio A. Edginton A.N. Blanchette V. Blatny J. Boban A. Cnossen M. Collins P. Croteau S.E. Fischer K. Hart D.P. Ito S. Korth-Bradley J. Lethagen S. Lillicrap D. Makris M. Mathôt R. Morfini M. Neufeld E.J. Spears J. Performing and interpreting individual pharmacokinetic profiles in patients with Hemophilia A or B: Rationale and general considerations. Res. Pract. Thromb. Haemost. 2018; https://doi.org/10.1002/rth2.12106 Crossref Scopus (44) Google Scholar ]. Due to the considerable interindividual variability of PK profiles, patients with prophylaxis of similar FVIII dosage and frequency could meet with quite different clinical outcomes. Thus, the PK parameters have played a very important role in individualizing the prophylaxis in patients with severe hemophilia A. Previous studies have reported that the PK profiles could be indicators of patients' bleeding patterns and could also be used to improve their personalized prophylaxis regimens. The bleeding was evaluated usually as annual bleeding rate (ABR) and annual joint bleeding rate (AJBR) in earlier studies. However, it is not easy to gain the exact bleeding details from pediatric patients. In addition, some subclinical bleeding without obvious feeling would also be easily ignored, which could also do irreversible damage to patients' joints [ [2] Di Minno M.N.D. Iervolino S. Soscia E. Tosetto A. Coppola A. Schiavulli M. Marrone E. Ruosi C. Salvatore M. Di Minno G. Magnetic resonance imaging and ultrasound evaluation of “healthy” joints in young subjects with severe haemophilia A. Haemophilia. 2013; https://doi.org/10.1111/hae.12107 Crossref Scopus (52) Google Scholar ]. With the development of medical terminology, advanced medical imaging tools like Ultrasound and MRI were able to detect pre-clinical changes in joint structure before obvious bleeds happened. These tools were also complied in treatment of hemophilia A and some scales to evaluate the joints were created and got used in previous studies [ [3] Poonnoose P.M. Hilliard P. Doria A.S. Keshava S.N. Gibikote S. Kavitha M.L. Feldman B.M. Blanchette V. Srivastava A. Correlating clinical and radiological assessment of joints in haemophilia: results of a cross sectional study. Haemophilia. 2016; https://doi.org/10.1111/hae.13023 Crossref Scopus (31) Google Scholar ]. We do this study to determine if there is a correlation between medical imaging test scales and time with trough level <1 IU/dL weekly. In addition, the consistency of US and other tests was also investigated to see if the US is suitable for routine monitoring.

Identifying hemophilia B carriers: Utility of aPTT, factor IX levels and ratios of factor IX to other Vitamin K dependent factors

PRO53 CLOTTING FACTOR UTILIZATION AND BLEEDING RATES AMONG PERSONS WITH HEMOPHILIA A FROM A LONGITUDINAL STUDY

Haemophilia Utilization Group Study – Part Va (HUGS Va): Design, Methods and Baseline Data

Association Between Health Status and Factor Consumption among Persons with Hemophilia B Using Propensity Score Matching

Carrier Detection and Prenatal Diagnosis of Hemophilia A.

Evaluation of Factor VIII Polymorphic Short Tandem Repeat Markers in Linkage Analysis for Carrier Diagnosis of Hemophilia A.

Carrier detection and prenatal diagnosis of haemophilia

Factor VIII and Factor IX Activity Measurements for Hemophilia Diagnosis and Related Treatments

Diagnosis and laboratory monitoring of hemophilia A

Clinical and molecular characteristics of hemophilia A affected individuals and carriers: A 24 years experience from three centers

The status of carrier and prenatal diagnosis of haemophilia in China.

Identification of Mutations in the F8 and F9 Gene in Families with Haemophilia Using Targeted High-Throughput Sequencing.

Limited value of testing for factor XIII and α2‐antiplasmin deficiency in patients with a bleeding disorder of unknown cause

[Congenital factor VII deficiency: a retrospective analysis of 43 cases].

Phenotype-genotype correlations in hemophilia A carriers are consistent with the binary role of the phase between F8 and X-chromosome inactivation

[Application of Long Distance-Pcr to Hemophilia A Carrier Detection and Prenatal Diagnosis].

A new hemophilia carrier nomenclature to define hemophilia in women and girls: Communication from the SSC of the ISTH

Bleeds and Imaging Scoring Scales in Relation to Pharmacokinetics of Coagulation Factor VIII in Chinese Pediatric Patients with Severe Hemophilia A.

Strategies for Performing Factor Assays in the Presence of Emicizumab or Other Novel/Emerging Hemostatic Agents

Proactive Systematic Hemophilia Carrier Screening: A Step Towards Gender Equity in Hemophilia Care

Relationship between plasma tissue Factor Pathway Inhibitor (TFPI) levels, thrombin generation and clinical risk of bleeding in patients with severe haemophilia A or B